Differential Metabolic Signature of Stroke Patients Undergoing Thrombolysis (DETECT)
Differential Metabolic Signature of Stroke Patients Undergoing Thrombolysis Compared to Healthy Controls
Currently, there is no reliable biomarker for stroke, meaning that treatment is often delayed and patients are often left with a disability. Stroke is one of the largest causes of mortality (death) and morbidity (disease) in the UK and affects around 120 and 15 people per 100,000 population. This has huge economic implications, with around £9 billion a year being spent on stroke in the UK alone, and health and social care costs accounting for half of this amount. Productivity losses (i.e. income costs) are estimated at £1.33 billion and benefit payments total £840 million per year.
Previous studies involving heart attack patients have suggested that succinate (a biomarker) levels rise after reperfusion (reoxygenation) of the heart tissue and in the context of ischaemia (i.e. when a restriction of blood supply to the heart has caused a heart attack and the tissue has been reoxygenated to improve blood flow around the body). Malonate is a therapeutic option to block this rise in succinate and reduce any potential resulting damage. Animal studies support these findings and have further shown that malonate prevents ischaemic brain damage and reduces the succinate increase in tissue.
However, there is currently no pre-clinical data for the release of succinate into blood, nor for stroke. This study aims to explore whether elevated succinate levels are present in stroke patients having thrombolysis (brain reperfusion). If we can show that elevated succinate levels are attributed to stroke (and not a result of thrombolysis), it might be possible to identify a therapeutic intervention at baseline for these patients and this reduce disability in all stroke patients, and healthcare costs in turn.
연구 개요
상태
정황
상세 설명
There are around 150,000 incidents of stroke every year in the UK alone. By the age of 75, 1 in 5 women and 1 in 6 men will have had a stroke; 26% of which will have occurred before the age of 65. Moreover, over half of all stroke survivors are left with a disability and 41% of these are discharged from hospital requiring help with daily activities. Without a reliable biomarker for stroke patients, the development of a therapeutic intervention at baseline which has the capability to reduce disability in stroke patients is not possible. There is a dire need for further research into stroke. In 2012, £56 million was spent on stroke-related care/research, compared to £544 million on cancer research and £166 million on heart disease.
Studies involving heart attack patients suggest that succinate could be used as a biomarker for stroke patients. Furthermore, the current therapeutic option used to block the rise in succinate levels, malonate, has been shown to prevent ischaemic brain damage in animal studies. No work to date has explored this phenomenon in humans with stroke and therefore this study has huge potential to bridge the gap in helping to treat stroke patients in the future and thus reduce healthcare costs.
The DETECT study is a pilot study and has been specifically designed to be as simple as possible. For stroke patients undergoing thrombolysis, they will already have a cannula inserted to aid with the procedure. We propose that research bloods could be taken from this same cannula to reduce the burden to the patient. Wherever possible we will conduct the safety follow-up with stroke patients whilst they are still an inpatient at the hospital, to again reduce the burden to the patient.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Cambridge, 영국
- Cambridge University Hospitals NHS Foundation Trust
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria (stroke patients):
- Be aged 18 years or over
- Present at Addenbrooke's Hospital A&E with a stroke (ischaemic stroke)
- Time of onset of confirmed stroke symptoms within 4 hours of arrival in ED
- Be eligible for thrombolysis
- Provide informed consent either prior to thrombolysis or after the initial emergency; or personal or nominated consultee declaration following the emergency
Inclusion Criteria (healthy volunteers):
- Be aged 18 years or over
- Provide informed consent
- Be healthy as determined by clinical history and examination by the investigator, a brief physical examination must be unremarkable.
Exclusion Criteria (stroke patients):
- Patients qualifying for thrombolysis but who do not give consent
- Patients under the age of 18
- Patients who are currently actively involved with another clinical trial (including observational studies)
Exclusion Criteria (healthy volunteers):
- Unable to provide informed written consent
- Participants under the age of 18
- Participants who are currently actively involved with another clinical trial (including observational studies)
- Any medical history or clinically relevant abnormality (from medical notes) that is deemed by the principal investigator and/or suitably qualified delegate to make the subject ineligible for inclusion
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
Stroke patients
환자는 표준 치료의 일부로 혈전 용해 치료를 받게 됩니다.
|
|
Healthy Volunteers
Healthy volunteers to act as control group for stroke patients.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Measurement of succinate in the same patients before and immediately after thrombolysis
기간: Up to 12 months
|
Up to 12 months
|
|
Baseline succinate measurement from age-matched healthy volunteers
기간: Up to 12 months
|
Up to 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Assessment of pre and post-thrombolysis blood from stroke patients vs healthy controls
기간: Up to 12 months
|
Bloods will be screened using a metabolomics scanner to identify if there are any significant changes in the data
|
Up to 12 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Thomas Krieg, MD, Cambridge University Hospital NHS Foundation Trust
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
뇌졸중, 허혈에 대한 임상 시험
-
Institut National de la Santé Et de la Recherche...모병